304873-80-1

Upstream product

• 175867-59-1 methyl 4-aminocyclohexane-1-carboxylate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 1776-53-0 4-aminocyclohexanecarboxylic acid 
• 130309-46-5 trans-4-(tert-butoxycarbonylamino)cyclohexane carboxylic acid 
• 503817-57-0 methyl 4-{[(tert-butoxy)carbonyl]amino}cyclohexane-1-carboxylate 

Downstream Products

• 505093-89-0 (4S)-3-[cis-(4-t-butoxycarbonylaminocyclohexyl)propenoyl]-4-phenylmethyl-2-oxazolidinone 
• 505093-89-0 (4S)-3-[trans-(4-t-butoxycarbonylaminocyclohexyl)propenoyl]-4-phenylmethyl-2-oxazolidinone 
• 947141-86-8 tert-butyl ((1r,4r)-4-ethynylcyclohexyl)carbamate 
• 1354280-36-6 C₁₄H₂₃N₃O₂ 
• 1354280-37-7 C₁₉H₃₁N₃O₄ 
• 1313365-97-7 4-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-1-methyl-piperazin-2-one 
• 1313365-98-8 [[2-(tert-butoxycarbonyl-methyl-amino)-ethyl]-(4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-amino]-acetic acid methyl ester 
• 1313365-94-4 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexylamino)-acetic acid methyl ester 
• 1313365-62-6 (4-{[(4-iodo-phenyl)-methyl-amino]-methyl}-trans-cyclohexyl)-carbamic acid tert-butyl ester 
• 1313363-54-0 (S)-1-(4-chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one 
• 1313365-58-0 {4-[(4-iodo-phenylamino)-methyl]-trans-cyclohexyl}-carbamic acid tert-butyl ester 
• 947141-86-8 tert-butyl (4-ethynylcyclohexyl)carbamate 

Relevant academic research and scientific papers

IRAK4 kinase inhibitor and preparation method thereof

The present invention provides a compound represented by a general formula I, and a pharmaceutically acceptable salt, a stereoisomer, an ester, a prodrug, a solvate and a deuterated compound thereof,and the compound is an IRAK4 kinase inhibitor, and can be used for prevention and/or treatment of IRAK4 related diseases, such as autoimmune diseases, inflammatory diseases, cancers, heteroimmune diseases, thromboembolism, atherosclerosis, myocardial infarction and metabolic syndrome.

HEPATITIS B CORE PROTEIN MODULATORS

The present disclosure provides, in part, compounds having allosteric effector properties against Hepatitis B virus Cp. Also provided herein are methods of treating viral infections, such as hepatitis B, comprising administering to a patient in need thereof a disclosed compound of formula:

SUBSTITUTED PYRAZOLO(1,5-A)PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS

The invention provides substituted pyrazolo[l,5-a]pyrimidine and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[l,5-a]pyrimidine compounds described herein include 5,7- dimethyl-N-phenylpyrazolo[l,5-a]pyrimidine-3-carboxamide compounds and variants thereof.

Synthesis and histamine H3 and H4 receptor activity of conformationally restricted cyanoguanidines related to UR-PI376

Recently, we identified highly potent agonists of the human histamine H4 receptor (hH4R) among a series of imidazolylbutylcyanoguanidines. Aiming at improved selectivity for the hH 4R relative to the H3 receptor

Total synthesis and absolute configuration of radiosumin, a strong trypsin inhibitor from the blue-green alga Plectonema radiosum

Radiosumin (1), a strong trypsin inhibitory dipeptide isolated from the freshwater blue-green alga Plectonema radiosum (NIES-515), was synthesized for the first time by use of the hetero Diels-Alder reaction, the Horner-Wadsworth-Emmons reaction, the Corey-Winter reaction, regioselective hydrogenation, and reduction with zinc and formic acid as key steps, which unambiguously determined the absolute configuration of the structurally unique and biologically intriguing aquatic natural product (1).

The synthesis of thrombin inhibitor L-370,518 via an α-hydroxy-β- lactam

We describe an efficient synthesis of thrombin inhibitor L-370,618 (1) via β-lactam 2. The synthesis of 2 is carried out in six steps from 4- aminocyclohexane carboxylic acid, with a yield of 27%.